A comparative study of intestinal Pseudomonas aeruginosa in healthy individuals and ICU inpatients

One Health Advances

Table 2 Antimicrobial susceptibility of P. aeruginosa from ICU inpatients and healthy individuals

Antimicrobial agent^a	ICU inpatients				healthy individuals				P value ^b
Antimicrobial agent^a	MIC₅₀ (μg/ml)	MIC₉₀ (μg/ml)	R%	S%	MIC₅₀ (μg/ml)	MIC₉₀ (μg/ml)	R%	S%	P value ^b
IPM	≤ 2	8	28.81	66.10	≤ 2	4	7.41	80.25	< 0.001
MEM	≤ 2	8	20.34	69.49	≤ 2	≤ 2	0.00	95.06	-
CAZ	≤ 2	64	20.34	76.27	≤ 2	≤ 2	0.00	100.00	-
FEP	4	32	11.86	79.66	≤ 2	≤ 2	0.00	100.00	-
AK	2	4	0.00	100.00	2	2	0.00	100.00	-
LEV	≤ 0.5	> 16	30.51	55.93	≤ 0.5	4	12.35	85.19	0.008
CIP	≤ 0.25	> 8	27.12	67.80	≤ 0.25	1	1.23	85.19	< 0.001
CO	1	1	0.00	100.00	1	1	0.00	100.00	-
TZP	≤ 8	128	15.25	77.97	≤ 8	≤ 8	0.00	98.77	-
SCF	≤ 8	64	13.56	76.27	≤ 8	≤ 8	0.00	100.00	-
ATM	≤ 4	32	11.86	66.10	≤ 4	8	0.00	98.77	-
CAV	2	8	3.39	96.61	1	2	0.00	100.00	-
GM	1	2	5.08	94.92	1	1	0.00	100.00	-

^a IPM Imipenem, MEM Meropenem, CAZ Ceftazidime, FEP Cefepime, AK Amikacin, LEV Levofloxacin, CIP Ciprofloxacin, CO Colistin, TZP Piperacillin/tazobactam, SCF Cefoperazone/sulbactam, ATM Aztreonam, CAV Ceftazidime/avibactam, GM Gentamicin
^b P value was calculated through the resistance rates between ICU inpatients and healthy individuals

ISSN: 2731-9970